Abiopharma

🔍 King Andrew James (Executive)

Company: Jade Biosciences, Inc. (JBIO)

Report Date: 2026-02-12

Detailed Transactions and Holdings:

• Acquired 41,250 shares of Common Stock (Direct)
  Date: 2026-02-12 | Code: A | equity_swap_involved: false | shares_owned_after: 386,113.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 247,500 shares of Stock Option (Right to Buy) at $14.81 per share (Derivative)
  Date: 2026-02-12 | Code: A | Expires: 2036-02-11 | equity_swap_involved: false | shares_owned_after: 247,500.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
• F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
• REMARKS: Chief Scientific Officer & Head of Research and Development